New injection targets hidden heart risk in early trial
Disease control
Not yet recruiting
This early-stage study tests a single dose of BSA204, an experimental injection, in 40 Chinese adults with borderline high lipoprotein(a) – a fatty substance linked to heart disease. The main goal is to check safety and side effects, while also measuring changes in cholesterol le…
Phase: PHASE1 • Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC